Every week I speak with patients who are building out longevity protocols. Many of them are already doing, or planning to do, some form of regenerative therapy: mesenchymal stem cells, exosomes, or PRP. They've done the research. They understand the science. They're making thoughtful investments in their health.
And most of them haven't thought about what they're putting those therapies into.
Here's a way I frame it. Imagine a fish tank filled with cloudy, stagnant water, the kind that's accumulated toxins over years of neglect. Now imagine dropping a healthy, carefully selected fish into that tank. The fish isn't the problem. The environment is. Within days, that fish is gone. Not because it wasn't viable, but because the conditions were incompatible with survival.
That's a reasonable model for what happens when we introduce regenerative therapies into an aged systemic environment. The therapies themselves may be excellent. But if the environment is working against them, you're not getting what you paid for.
What's Actually in Aged Plasma
When we talk about an "aged" or "inflammatory" environment, we're talking about something measurable and specific, not a vague sense of being run-down.
As we age, plasma accumulates proteins that actively suppress the body's ability to repair and regenerate. Two of the most well-studied are TGF-β1 and GDF11, proteins that, at elevated levels, tell stem cells to stay dormant rather than activate. Alongside these, aging cells throughout the body release a steady stream of inflammatory signals into the bloodstream: a mix of cytokines, enzymes, and growth-inhibiting factors that build up over time.
The important distinction is this: aged plasma isn't simply missing the good stuff. It is actively carrying molecules that work against regeneration. These aren't the same problem, and they don't have the same solution.
A 2020 study in Aging by Mehdipour and colleagues, co-authored by Dr. Dobri Kiprov, demonstrated this directly. Researchers exposed mouse muscle stem cells to plasma collected from aged human subjects, before and after a single session of therapeutic plasma exchange. Pre-TPE plasma kept the cells dormant. Post-TPE plasma, where those inhibitors had been substantially diluted, produced immediate activation and proliferation.
Same cells. Same conditions. The only variable was the plasma — and its effect was powerful enough to suppress regenerative activity across species lines.
Why This Matters for Stem Cells, Exosomes, and PRP
The problem doesn't affect all regenerative therapies in exactly the same way, but it affects all of them.
Stem cells do their work by sending signals, chemical messages that tell surrounding tissue to repair, rebuild, and regenerate. But those signals don't travel in a vacuum. When the environment is already flooded with inflammatory proteins, it's like trying to have an important conversation in a room where everyone is shouting. The message exists. It just can't get through.
Exosomes work the same way. They're essentially tiny delivery vehicles carrying instructions to your cells: growth factors, proteins, and other molecules that tell damaged tissue how to heal. The quality of the delivery depends heavily on whether the receiving environment is in a state to listen. A system saturated with the proteins that accumulate in aged blood isn't a receptive environment. It's a hostile one.
PRP is worth addressing separately, because there are actually two problems, not one.
The first is the same issue as above: growth factors being delivered into a tissue environment that's working against them. PRP floods the target area with regenerative signals, but if the surrounding tissue is chronically inflamed, those signals are fighting an uphill battle.
The second problem is more fundamental. PRP is made from your own blood plasma, the same plasma that, in an aged or inflamed system, is carrying elevated levels of the very inflammatory proteins we've been discussing. Concentrating that plasma and reinjecting it doesn't just introduce growth factors. It concentrates everything in the sample, including the inflammatory markers. In that setting, you're not just working against a headwind. You're amplifying the problem.
This is where the sequencing argument becomes particularly direct for PRP patients. Plasma exchange meaningfully reduces the inflammatory burden in circulating blood. PRP drawn after TPE starts from a cleaner baseline: lower inflammatory markers and a more favorable ratio of regenerative to inhibitory factors. The procedure is the same. The raw material is better.
Not Just Reducing the Noise — Improving the Signal
"The question isn't just whether your regenerative therapy is high quality. It's whether the environment it's entering is capable of responding to it."
This is where therapeutic plasma exchange enters the picture. Not as a regenerative therapy itself, but as a preparation step that changes the conditions under which regenerative therapies operate.
TPE removes a large portion of the aged plasma proteins circulating in your blood, including the inflammatory cytokines, TGF-β1, GDF11, and other factors that actively suppress regenerative signaling, and replaces them with albumin and saline. But the effect isn't only subtractive.
A 2022 clinical study in GeroScience by Kiprov and colleagues measured this directly in humans, and the findings went beyond simply reducing harmful proteins. Patients showed significant reductions in p16 (a marker of cellular aging) and decreases in DNA damage markers. Critically, the study also documented meaningful changes at the proteomics level: inflammatory proteins decreased while regenerative ones increased. TPE doesn't just quiet the noise. It shifts the balance of the environment toward less suppression and more of the signals that support repair and renewal.
"TPE doesn't replace regenerative therapy. It creates the conditions under which regenerative therapy has a better chance of working."
A 2025 review in Ageing Research Reviews by Akgun and Kiprov built on this further, describing TPE as a systemic strategy for reducing the accumulated inflammatory signals that make the regenerative environment hostile, and by extension, for creating conditions where regenerative therapies have a better chance of working.
Sequencing as Strategy
None of this is an argument against stem cells, exosomes, or PRP. These modalities have real science behind them, and for many patients they're a meaningful part of a longevity protocol.
The argument is about sequencing. If you're making a significant investment in regenerative medicine, it's worth asking what environment those therapies are entering. And if that environment is measurably hostile, loaded with the inhibitory proteins that research has characterized clearly, addressing it first is the logical move.
Clean the tank before you introduce anything you expect to thrive in it.
A Note on Evidence
The mechanistic case here is that aged plasma contains active inhibitors of regeneration, that TPE measurably reduces those inhibitors while increasing beneficial factors, and that the resulting environment is more receptive to regenerative signaling. This is supported by preclinical and human clinical data. The Mehdipour 2020 experiment demonstrates the inhibitor mechanism directly. The Kiprov 2022 clinical study shows measurable shifts in both inflammatory and regenerative proteins in human subjects.
What we don't yet have is large-scale randomized trial data evaluating TPE specifically as a preparatory step before regenerative therapy. Patients building complex protocols deserve to understand that distinction. The mechanistic argument is well-supported. Full clinical validation is where the field is heading.